Utilizing pharmacogenetics when treating first episode psychosis.

J Psychiatry Neurosci

From the Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Que. (Korchia, Joober, Sabesan, Palaniyappan); the Lakeshore Hospital, Department of Psychiatry, McGill University, Montreal, Que. (Sabesan, Palaniyappan); the Robarts Research Institute, Western University, London, Ont. (Sabesan, Palaniyappan); the Department of Psychiatry, La Conception University Hospital, Marseille, France (Korchia, Richieri); CNRS, Centrale Marseille, Institut Fresnel, Aix Marseille University, Marseille, France (Korchia, Richieri).

Published: January 2023

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829032PMC
http://dx.doi.org/10.1503/jpn.220154DOI Listing

Publication Analysis

Top Keywords

utilizing pharmacogenetics
4
pharmacogenetics treating
4
treating episode
4
episode psychosis
4
utilizing
1
treating
1
episode
1
psychosis
1

Similar Publications

Background: Few new psychiatric drugs have entered the market in recent decades; in contrast, the number of drugs carrying pharmacogenomic labels continues to increase. For the foreseeable future, the advancement of psychiatry and drug therapy may hinge on personalized treatment. Currently, antipsychotic or antidepressant choices rely heavily on the clinical experience of psychiatrists and potentially lengthy iterative trials.

View Article and Find Full Text PDF

Serum C-reactive protein (CRP) levels vary depending on radiological and bacteriological findings at the time of tuberculosis (TB) diagnosis. However, the utility of this biomarker in monitoring response to anti-TB treatment and identifying patients at risk of treatment failure is not well established. This study evaluated the impact of patients' baseline characteristics and anti-TB drug plasma exposure on the early reduction in serum CRP levels and its relationship with treatment response.

View Article and Find Full Text PDF

Integration of pharmacogenetic data in epic genomic module drives clinical decision support alerts.

Front Pharmacol

December 2024

Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, United States.

Introduction: The Precision Medicine Program (PMP) at the University of Florida (UF) focuses on advancing pharmacogenomics (PGx) to improve patient care.

Methods: The UF PMP, in collaboration with the UF Health Pathology Laboratory (UFHPL), utilized Health Level Seven (HL7) standards to integrate PGx data into Epic's Genomic Module to enhance the management and utilization of PGx data in clinical practice.

Results: A key feature of the Genomic Module is the introduction of genomic indicators-innovative tools that flag actionable genetic information directly within the electronic health record (EHR).

View Article and Find Full Text PDF

Brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) are known to contribute to both protective and pronociceptive processes. However, their contribution to neuropathic pain after spinal cord injury (SCI) needs further investigation. In a recent study utilizing TrkB mice, it was shown that systemic pharmacogenetic inhibition of TrkB signaling with 1NM-PP1 (1NMP) immediately after SCI delayed the onset of pain hypersensitivity, implicating maladaptive TrkB signaling in pain after SCI.

View Article and Find Full Text PDF

Objective: Prostate cancer (PCa) is the most common cause of cancer-related deaths in men worldwide. BRCA1/2 genes are reported altered in approximately 1% and 8% of PCa cases, respectively. To date, formalin-fixed paraffin-embedded (FFPE) tissues have a consolidate use in the clinical practice, but with a significant drawback related to DNA/RNA degradation during the pre-analytical process.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!